Amarin Corporation plc Sponsored ADR (AMRN)
Summary
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
AMRN surpasses Q2 earnings estimates despite lower revenues, as cost cuts, rising demand and global partner-driven growth shape its ongoing transformation.
Amarin Q2 Earnings Call Highlights
Amarin NASDAQ: AMRN said its second-quarter results reflected progress in its dual commercial strategy, which combines a company-managed U.S. business with partnered commercialization internationally. Management highlighted growing demand for VASCEPA in Europe, cost reductions from a completed restructuring program and a third consecutive quarter of positive operating cash flow.
Amarin Corporation plc Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 98 | $1,589.56 | $1,372.98 | -$216.58 | -13.63% |
| NA Nizar Araji National Bank Of Canada /FI/ | 2,518 | $36,471.88 | $36,158.48 | -$313.4 | -0.86% |
 John Nowicki LCM Capital Management Inc. | 51,362 | $828,767.64 | $732,422.12 | -$96,345.52 | -11.63% |
 Sima Elimelech Activest Wealth Management | 50 | $811 | $713 | -$98 | -12.08% |
 Dinan Hu R Squared Ltd | 16,938 | $269,992 | $241,535.88 | -$28,456.12 | -10.54% |
Amarin Corporation plc Sponsored ADR (AMRN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amarin Corporation plc Sponsored ADR ever had a stock split?
Amarin Corporation plc Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Aaron D. Berg CEO | NASDAQ (CM) Exchange | 023111404 CUSIP |
| IE Country | 80 Employees | - Last Dividend | 11 Apr 2025 Last Split | - IPO Date |
Overview
Amarin Corporation plc stands as a noteworthy entity within the pharmaceutical landscape, dedicating its efforts to developing and commercializing therapeutic treatments aimed at combating cardiovascular diseases. With a geographical footprint spanning the United States, various European countries, Canada, Lebanon, and the United Arab Emirates, Amarin has established a significant presence in the global healthcare sector. The company's journey began under the name Ethical Holdings plc but underwent a rebranding to Amarin Corporation plc in 1999, marking a new chapter in its history. Since its inception in 1989, Amarin has been headquartered in Dublin, Ireland, serving as a testament to its enduring commitment to advancing cardiovascular health through innovative pharmaceutical solutions. At the heart of its collaborative endeavors is a strategic partnership with Mochida Pharmaceutical Co., Ltd., focusing on the development and commercialization of drug products and new therapeutic indications derived from the active pharmaceutical ingredient in its flagship product, Vascepa.
Products and Services
- VASCEPA
VASCEPA stands out as Amarin Corporation plc's premier product offering, distinguished by its formulation as a prescription-only omega-3 fatty acid. This distinctive pharmacological product is specifically designed as an adjunct to diet for the purpose of reducing triglyceride levels in adult patients diagnosed with severe hypertriglyceridemia. The commercialization of VASCEPA primarily targets wholesalers and specialty pharmacy providers, thereby ensuring its accessibility to the patient population in need of this critical intervention for managing cardiovascular health. Through this endeavor, Amarin accentuates its commitment to addressing the intricate challenges associated with cardiovascular diseases, leveraging the therapeutic potential of omega-3 fatty acids to enhance patient outcomes.
